Clinical trial for Diffuse Large B Cell Lymphoma
Official title A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
ClinicalTrials.gov ID: NCT06736613
What this study is testing
- What it's testing
- The study wants to know how many high‑risk B‑cell lymphoma patients have tumor DNA in their cerebrospinal fluid even when standard tests show no CNS disease, and how often CNS relapse occurs in those with and without detectable ctDNA.
- Who it's for
- Adults with B‑cell lymphoma who are considered at high risk for cancer spreading to the brain or spinal cord.
- What's involved
- Participants will have a spinal‑fluid (CSF) sample taken to test for circulating tumor DNA and will continue their usual care and monitoring.
- Time commitment
- A single clinic visit for the spinal‑fluid collection (and any routine follow‑up visits required by the study).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Signed Informed Consent.
- Ability and willingness to comply with the requirements of the study protocol.
- Age ≥ 18 years old.
- Diffuse Large B-cell Lymphoma (DLBCL) with CNS IPI score ≥ 4.
- Stage III/IV High Grade B-cell lymphoma (HGBCL) with MYC, BCL2, and/or BCL6 translocations
You likely can't join if
- Active systemic therapy for another malignancy (other than indolent B-cell lymphoma) within 2 years
- Active concurrent malignancy with the exception of basal cell or localized squamous cell skin carcinoma, localized prostate cancer, or other...
- Any uncontrolled illness that in the opinion of the investigator would preclude administration of curative intent chemoimmunotherapy (e.g.
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment...
- Psychiatric illness or social situations that would limit the patient's ability to tolerate and/or comply with study requirements.
See the full eligibility criteria
- Signed Informed Consent.
- Ability and willingness to comply with the requirements of the study protocol.
- Age ≥ 18 years old.
- Diffuse Large B-cell Lymphoma (DLBCL) with CNS IPI score ≥ 4.
- Stage III/IV High Grade B-cell lymphoma (HGBCL) with MYC, BCL2, and/or BCL6 translocations
- Primary DLBCL of Breast
- Primary DLBCL of Testis
- Primary Cutaneous DLBCL, Leg Type
- Intravascular Large B-cell Lymphoma
- Stage III/IV HIV-associated DLBCL
- Double expressor DLBCL (co-expression of MYC ≥ 40% and BCL2 ≥ 50% without translocations) with a CNS IPI score ≥ 3
- DLBCL with the following extranodal involvement AND CNS IPI score ≥ 3: i. Adrenal ii. Breast iii. Bone Marrow with pathological overt morphological involvement iv. Epidural/Paraspinal v.
- Transformed DLBCL from any indolent B-cell lymphoma is permitted (as long as there is no prior history of CNS involvement).
- Planned to receive standard chemoimmunotherapy.
- Patient is able to undergo lumbar puncture without any contraindications which include but are not limited to altered mental status, increased intracranial pressure due to any CNS lesion (mass, abscess), overlying skin...
- No systemic therapy prior to study enrollment for an aggressive B-cell lymphoma is permitted. Treatment for a history of indolent lymphoma is permitted.
- ECOG performance status of 0 to 2.
- Active systemic therapy for another malignancy (other than indolent B-cell lymphoma) within 2 years
- Active concurrent malignancy with the exception of basal cell or localized squamous cell skin carcinoma, localized prostate cancer, or other localized carcinomas such as carcinoma in situ of cervix, breast, or bladder.
- Any uncontrolled illness that in the opinion of the investigator would preclude administration of curative intent chemoimmunotherapy (e.g.
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV...
- Psychiatric illness or social situations that would limit the patient's ability to tolerate and/or comply with study requirements.
The study team makes the final eligibility decision.
Where it is enrolling
- Basking Ridge, New Jersey, United States
- Middletown, New Jersey, United States
- Montvale, New Jersey, United States
- Commack, New York, United States
- Harrison, New York, United States
- New York, New York, United States
- Rockville Centre, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Basking Ridge, New Jersey, United States; Middletown, New Jersey, United States; Montvale, New Jersey, United States; Commack, New York, United States; Harrison, New York, United States; New York, New York, United States and 1 more location. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.